Alkermes, Inc.
10 drugs in NADAC|0 Generic,10 Brand
View Recalls (3)Alkermes, Inc. lists 10 NDCs in the CMS NADAC file (0 generic, 10 brand), at an average NADAC of $695.24 per unit, with a week-over-week move of +0.2% across products that moved. The firm's full portfolio, pricing trend, and FDA recalls are listed below.
Total Drugs
10
0G / 10B
Avg Price / Unit
$695.2380
$55.05 – $1717.19
Avg 7d Change
+0.18%
Across 9 drugs with changes
7d Activity
of 10 total drugs
Portfolio Price Trend
Monthly average NADAC price across all drugs
Frequently Asked Questions
How many drugs does Alkermes, Inc. make?
Alkermes, Inc. lists 10 NDCs in the CMS NADAC file — 0 generic and 10 brand products.
What is the average price of Alkermes, Inc. drugs?
The average NADAC across Alkermes, Inc.'s portfolio is $695.2380 per unit, ranging from $55.0457 to $1717.1886.
What types of drugs does Alkermes, Inc. make?
Alkermes, Inc. makes drugs across 2 FDA pharmacologic classes. The most common by NDC count are Atypical Antipsychotic (9), Opioid Antagonist (4).
Has Alkermes, Inc. had any drug recalls?
3 FDA recalls are matched to Alkermes, Inc. in the openFDA feed, most recently on Sep 26, 2019.
How has Alkermes, Inc.'s pricing changed recently?
Over the past 7 days, 6 Alkermes, Inc. products rose and 3 fell, with a portfolio-wide average change of +0.2%.
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
VIVITROL 380 MG VIAL-DILUENT naltrexone | $1717.1886 per EA | +0.07% |
ARISTADA INITIO ER 675 MG/2.4 aripiprazole lauroxil | $1026.9112 per ML | — |
ARISTADA ER 662 MG/2.4 ML SYRN aripiprazole lauroxil | $1005.8851 per ML | +0.70% |
ARISTADA ER 882 MG/3.2 ML SYRN aripiprazole lauroxil | $1001.0139 per ML | +0.17% |
ARISTADA ER 441 MG/1.6 ML SYRN aripiprazole lauroxil | $991.8102 per ML | +0.75% |
ARISTADA ER 1,064 MG/3.9 ML SYR aripiprazole lauroxil | $988.9842 per ML | +0.14% |
LYBALVI 5-10 MG TABLET olanzapine and samidorphan L-malate | $55.2814 per EA | -0.09% |
LYBALVI 15-10 MG TABLET olanzapine and samidorphan L-malate | $55.1334 per EA | +0.07% |
LYBALVI 10-10 MG TABLET olanzapine and samidorphan L-malate | $55.1262 per EA | -0.01% |
LYBALVI 20-10 MG TABLET olanzapine and samidorphan L-malate | $55.0457 per EA | -0.17% |
FDA Recalls (3)
Recalls matched by company name. Verify current status with FDA.
Vivitrol (naltrexone for extended-release injectable suspension) 380 mg/vial. Each Carton Contains: 1) One vial of 380 mg of Vivitrol, 2) One vial containing 4 mL of diluent, 3) One 5-mL prepackaged syringe, 4) One 20-gauge 1-inch needle, 5) Two 20-gauge 1.5-inch safety needles, 6) Two 20-gauge 2-inch safety needles. Rx Only. Manufactured and marketed by: Alkermes, Inc. Kit NDC: 65757-300-01
Labeling: Not Elsewhere Classified. Drug product kit recalled due to 1 inch needles being placed in the 1 1/2 inch needle cardboard sleeve labelled as administration needles. The product vial is not impacted.
VIVITROL (naltrexone for extended-release injectable suspension); 380 mg vial NDC 65757-300-01; RX Only Manufactured and marketed by Alkermes, Inc., Waltham, MA 02451.
Customer complaints for failure to deliver the dose.
VIVITROL (naltrexone for extended-release injectable suspension) a) 380 mg vial NDC 65757-303-02, b) 380 mg vial in kit NDC 65757-300-01, Rx Only Manufactured and marketed by Alkermes, Inc., Waltham, MA 02451,
Lack of Assurance of Sterility: Product did not meet the criteria for container closure integrity testing during routine 24 month stability testing.